About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT06668324

Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation

The study aims to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation

Lead sponsor: Novartis Pharmaceuticals•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Novartis Pharmaceuticals

Age

18 - 99 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Ability to use a mobile device or computer with broadband internet access (or data streaming available)
•2. Ability to read, understand, and respond in English
•3. Adult aged 18 years of age or over at the time of the survey
•4. Self-confirmed diagnosis of MS
•5. Prescribed either OMB or OCR SC and will receive their first injection (Day 0) followed by completing the study survey between Day 1 and Day 7

Exclusion Criteria

•1. Participated in an OMB or OCR randomized clinical trial
•2. Previously treated with OMB or OCR SC
•3. Cognitive impairment that impacts the patient's ability to participate in a survey study

Related studies

RECRUITINGPhase 3

A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

NCT07189325 · Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy

Development of Pain Management JITAI Content in Multiple Sclerosis and Spinal Cord Injury

NCT07663266 · Multiple Sclerosis, Spinal Cord Injury

RECRUITINGPhase 2

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

NCT06170970 · Multiple Sclerosis, Multiple Sclerosis Fatigue

RECRUITINGPhase 2

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

NCT06782490 · Multiple Sclerosis Spasticity

RECRUITINGPhase 3

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

NCT07299019 · Secondary Progressive Multiple Sclerosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 19, 2025Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment134

Start dateNov 2024

Last updatedSep 19, 2025

Condition

Multiple Sclerosis

Locations shown

Novartis Investigative site

East Hanover, New Jersey

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 19, 2025Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions